Lowenthal Richard E 4
4 · ARS Pharmaceuticals, Inc. · Filed Nov 14, 2024
Insider Transaction Report
Form 4
Lowenthal Richard E
DirectorPRESIDENT AND CEO10% Owner
Transactions
- Sale
Common Stock
2024-11-12$16.76/sh−45,045$754,905→ 1,301,449 total(indirect: By Trust) - Sale
Common Stock
2024-11-12$17.64/sh−4,955$87,421→ 1,296,494 total(indirect: By Trust) - Sale
Common Stock
2024-11-12$16.76/sh−45,124$756,296→ 1,253,375 total(indirect: By Trust) - Sale
Common Stock
2024-11-12$17.64/sh−4,876$86,020→ 1,248,499 total(indirect: By Trust)
Holdings
- 1,397,447(indirect: By Trust)
Common Stock
- 3,407,847(indirect: By Spouse)
Common Stock
- 4,315,313
Common Stock
Footnotes (8)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.
- [F2]The weighted average sale price for the transaction reported was $16.7589, and the range of prices were between $16.405 and $17.395. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]The Reporting Person is trustee of the trust.
- [F4]The weighted average sale price for the transaction reported was $17.643, and the range of prices were between $17.42 and $17.85. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F5]The weighted average sale price for the transaction reported was $16.7604, and the range of prices were between $16.40 and $17.39. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F6]The shares are held in trust for the benefit of the Reporting Person and his spouse. The Reporting Person and his spouse are trustees of the trust.
- [F7]The weighted average sale price for the transaction reported was $17.6416, and the range of prices were between $17.42 and $17.83. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F8]The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.